Print this page
Radiation
-
A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684 Based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Protocol: 082408Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer.
Protocol: 082413Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma STRIKE
Protocol: 082502Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-ZZFX (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Protocol: 102301Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Protocol: 102302Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers.
Protocol: 102402Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers.
Protocol: 102405Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Corpus Uteri
Ovary -
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-Sensitive Recurrent Ovarian Cancer (TroFuse-022/GOG-3103/ENGOT-ov84).
Protocol: 102501Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR alpha-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Protocol: 102502Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase III Study Of Induction Pembrolizumab And Chemotherapy Followed By Chemoradiation And Pembrolizumab Vs Chemoradiation And Pembrolizumab Both Followed By Pembrolizumab For High Risk Locally Advanced Cervical Cancer.
Protocol: 102507Principal Investigator:
- Ana Tergas
Applicable Disease Sites: Cervix -
A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab versus Carboplatin, Paclitaxel, Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab In The Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer.
Protocol: 102601Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
- Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL).
Protocol: 111803Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site